Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -0.12% 834.00p 834.00p 834.50p 835.00p 834.00p 835.00p 123,713 15:20:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 620.5 -70.6 3.9 213.8 3,231.17

Btg Share Discussion Threads

Showing 5101 to 5123 of 6175 messages
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
18/1/2018
17:36
That's years away.There is a short term blip , with more bad news blips than good news blips.
bargainbob
18/1/2018
17:33
BB, Varithena will probably come good.
retsig
18/1/2018
17:29
Another hole in BTG earnings , cannot understand why the share price is holding up. What good news I'am missing.
bargainbob
18/1/2018
15:10
Hard to say but they paid us 70m in the last results . But it will take a while for the generic drugs to get into the market anyway and wont mean that sales will just dry up .
king1pin2
18/1/2018
13:03
so whats the inpact to BTG £20 million a year ?
bargainbob
18/1/2018
10:09
seems to be holding above 710
estienne
18/1/2018
09:45
We wont be the ones that foot that bill tho.
king1pin2
18/1/2018
09:15
'Obviousness' is a very difficult area of patent law.The US Patent office will have a very detailed protocol for dealing with it and the Appeal court will follow that carefully to ensure that there is real substance behind any appeal.Lots of money for expensive lawyers.The US government interest will be to lower health costs.Not going to be sorted out in the short term!
fhmktg
18/1/2018
09:14
what does it mean “ 30 Months ! stay triggered «
a1ord53
18/1/2018
08:56
NEW BRUNSWICK, N.J., Jan. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate): "We are disappointed in and strongly disagree with the U.S. Patent and Trademark Office's (USPTO) decisions relating to ZYTIGA® as part of the Inter Partes Reviews. We are evaluating our options with respect to a request for rehearing and/or appeal to the Court of Appeals for the Federal Circuit. We believe the '438 patent is valid and will continue to vigorously defend it." Inter Partes Review decisions by the USPTO do not result in termination of a 30-month stay triggered under the Hatch-Waxman Act by the timely filing of a patent infringement lawsuit against a generic ANDA applicant.
spyder
18/1/2018
08:52
That's a blow for J&J as well as for our cash flow!
fhmktg
18/1/2018
08:47
No a zytiga patent loss in the US
dp1umb
18/1/2018
08:31
That's a fierce start to the day! Just traders?
fhmktg
11/1/2018
17:33
Wonder who sold the big chunks . Woodford ?
bargainbob
11/1/2018
15:38
And another 200k....
fhmktg
11/1/2018
13:56
Two buys of 330k....promising!
fhmktg
08/1/2018
17:32
That's the new year down trend under way then .
bargainbob
02/1/2018
11:48
I think BTG has more impact on financials than any external influence . Three years of multi million own goals . Hopefully in the past. Too be fair surprised it not testing the £6 mark yet .
bargainbob
02/1/2018
09:20
Any thoughts on the impact of Trump's tax reforms on BTG's financials.At least there should be some effect from personal tax reductions for the higher income groups on spending on health?Do btg pay us corporation tax on their us activities?Some underpinning of the $/£ exchange rate should help profits in sterling and there may be some further strengthening of the dollar.
fhmktg
29/12/2017
11:33
Very satisfying year end, I'm showing a near 32% rise over the year.All the best to holders for 2018!
fhmktg
28/12/2017
09:21
Thanks, different meaning up in Scotland lol Patients are the number one priority at ASD Healthcare. We affirm this commitment daily in our True Blue culture—which is our way of delivering exceptional services to our healthcare partners and the patients they serve. Many people define True Blue as a loyal, dependable and trustworthy person whom others count on. At ASD Healthcare, our associates put those words into action each day by going above and beyond expectations. Our innovative products and exceptional customer service make us the largest distributor of oncology and supportive care products to healthcare facilities and specialty pharmacies. Our knowledge, reach and partnerships position us as the number one distributor of blood derivatives, nephrology products and critical specialty pharmaceutical products in the U.S. We maintain solid relationships with all major specialty pharmaceutical manufacturers, and are the trusted partner of all major GPOs. That’s why 95 percent of U.S. hospitals are our active customers, and why other healthcare providers depend on us to deliver innovative products and services. When founded in 1993, ASD Healthcare was originally known as Alternate Site Distributors. Our name was changed to Advanced Specialty Distribution (ASD) in 1997, when our customer base expanded to health systems. Then a subsidiary of Bergen Brunswick Drug Corporation, ASD Healthcare became a part of AmerisourceBergen Specialty Group when AmerisourceBergen Corporation was formed in 2001.
bargainbob
28/12/2017
09:00
Ps do you have a link , tried to find it , only found a few cartoon like videos .
bargainbob
28/12/2017
08:54
Does it say what year fhmktg lol
bargainbob
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
Your Recent History
LSE
BTG
Btg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190618 14:38:00